FENNEC PHARMACEUTICALS INC.
FENNEC PHARMACEUTICALS INC. (FENC) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Fennec Pharmaceuticals Announces ORAL PRESENTATION OF DETAILED Results From Investigator-Initiated Phase 2 STS-J01 Clinical Study of PEDMARK ® in Japan AT SIOP 2026 ~ Primary Endpoint Met: American Speech-Language-Hearing Association (ASHA)-Defined Hearing Loss Occ
Fennec Pharmaceuticals (FENC) will present detailed Phase 2 Pedmark trial results at SIOP 2026. The study evaluated Pedmark's ability to reduce cisplatin-induced hearing loss in Japanese pediatric patients. Pedmark is FDA-approved for this indication. FENC stock is up 2.75% at $10.84.
Sayad Pierre Sargis (Chief Medical Officer) sold 12,000 shares of FENNEC PHARMACEUTICALS INC. (FENC) at $12.18 ($0.15M total) on 2026-08-31.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning FENC (FENNEC PHARMACEUTICALS INC.). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent FENC coverage spans insider activity, corporate actions and earnings.
In the last 30 days, FENC insiders filed 4 SEC Form 4 transactions — no purchases and 4 sales ($1.3M). The most active reporter was Raykov Rosty with 1 filing. 75% of those filings were made under pre-arranged Rule 10b5-1 plans.
Positive trial data could boost stock on anticipated regulatory filing and partnership interest.
Potential positive impact if data are favorable; neutral until results released.
Insider sale may signal reduced confidence or portfolio rebalancing, modest negative pressure on the stock.
Insider sale may signal CFO's view on near-term valuation.
Q2 profitability and cash runway details, alongside ongoing PEDMARK clinical and Japan trial presentation plans, can shift near-term sentiment and positioning.
AlphAI scores every news story that mentions FENC with an AI model for sentiment and relevance, and aggregates insider trades from FENNEC PHARMACEUTICALS INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
FENNEC PHARMACEUTICALS INC. (FENC) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Fennec Pharmaceuticals Announces ORAL PRESENTATION OF DETAILED Results From Investigator-Initiated Phase 2 STS-J01 Clinical Study of PEDMARK ® in Japan AT SIOP 2026 ~ Primary Endpoint Met: American Speech-Language-Hearing Association (ASHA)-Defined Hearing Loss Occ
2 min readFennec Pharmaceuticals (FENC) will present detailed Phase 2 Pedmark trial results at SIOP 2026. The study evaluated Pedmark's ability to reduce cisplatin-induced hearing loss in Japanese pediatric patients. Pedmark is FDA-approved for this indication. FENC stock is up 2.75% at $10.84.
1 min readSayad Pierre Sargis (Chief Medical Officer) sold 12,000 shares of FENNEC PHARMACEUTICALS INC. (FENC) at $12.18 ($0.15M total) on 2026-08-31.
1 min readAndrade Robert (CHIEF FINANCIAL OFFICER) sold 75,000 shares of FENNEC PHARMACEUTICALS INC. (FENC) at $11.78 ($0.88M total) on 2026-08-27 under a Rule 10b5-1 trading plan.
1 min readFennec Pharmaceuticals (NASDAQ:FENC) reported Q2 results on an earnings call. Net product sales were $17.1 million, up 78% year over year. Non-GAAP adjusted EBITDA was $2.8 million versus a $1.2 million loss a year earlier. Cash and cash equivalents were $41.2 million at June 30, 2026. Management cited PEDMARK momentum and no quantitative 2026 revenue outlook.
6 min readFennec Pharmaceuticals (NASDAQ:FENC) shares rose about 8% premarket after Q2 results beat estimates. Adjusted EPS was $0.05 vs $0.02 consensus. Revenue was $17.87M vs $16.39M forecast. Net product sales for PEDMARK grew 78% to $17.1M. Adjusted EBITDA turned positive at $2.8M vs a $1.2M loss. Cash was $41.2M.
4 min readInsider Monkey highlights nine companies that beat Q2 EPS expectations among 350+ firms reporting by Aug. 11. Reported EPS surprises include RideNow Group (RDNW) $0.16 vs $0.13, Anterix (ATEX) $0.01 vs -$0.17, Super Micro Computer (SMCI) $1.70 vs $0.96, and Fennec Pharmaceuticals (FENC) $0.05 vs $0.01. The rest of the piece shifts to AI themes and promotional content.
7 min readBiotech stocks hit 52-week highs Aug. 7, 2026. Halozyme (HALO) rose 20% after Q2 revenue of $481M (+48% Y/Y) and 2026 revenue guidance of $1.83B-$1.91B. Fennec (FENC) reached $11.66 on PEDMARK sales of $15.1M (+71% Y/Y). Avalyn (AVLN) hit $34.15. Amylyx (AMLX) hit $24.60. Chemed (CHE) rose to $552.72 after Q2 revenue $673M (+8.8%) and 2026 growth guidance of 8.25%-9.25%.
7 min readFENNEC PHARMACEUTICALS INC. (FENC) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001211583 0001211583 2026-06-10 2026-06-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
2 min readRaykov Rosty sold 9,747 shares of FENNEC PHARMACEUTICALS INC. (FENC) at $9.62 on 2026-06-01 under a Rule 10b5-1 trading plan.
2 min read
